Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vincerx Pharma's share price for the quarter that ended in Mar. 2025 was $0.5294. Vincerx Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 5.23 Mil. Therefore, Vincerx Pharma's market cap for the quarter that ended in Mar. 2025 was $2.77 Mil.
Vincerx Pharma's quarterly market cap
declined
from Sep. 2024 ($22.48 Mil) to Dec. 2024 ($11.77 Mil) and
declined
from Dec. 2024 ($11.77 Mil) to Mar. 2025 ($2.77 Mil).
Vincerx Pharma's annual market cap
increased
from Dec. 2022 ($21.66 Mil) to Dec. 2023 ($25.25 Mil) but then
declined
from Dec. 2023 ($25.25 Mil) to Dec. 2024 ($11.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vincerx Pharma's Enterprise Value for Today is $-4.92 Mil.
Vincerx Pharma (OTCPK:VINC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vincerx Pharma Market Cap Related Terms
Vincerx Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Vincerx Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vincerx Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vincerx Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Vincerx Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vincerx Pharma's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincerx Pharma (VINC) has a Market Cap of $0.07 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vincerx Pharma and its competitors.
Is Vincerx Pharma's Market Cap too high?
Vincerx Pharma's current Market Cap is $0.07 Mil. The Biotechnology industry median Market Cap is 113.83. Vincerx Pharma's value of $0.07 Mil is 99.9% below this industry median.
How does Vincerx Pharma's Market Cap compare to SYGGF and CNBX?
Vincerx Pharma's Market Cap of $0.07 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 113.83. Vincerx Pharma's value of $0.07 Mil is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vincerx Pharma's current Market Cap of $0.07 Mil is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vincerx Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vincerx Pharma's current Market Cap is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincerx Pharma stock overvalued right now?
Vincerx Pharma (VINC) has a current Market Cap of $0.07 Mil. The current Market Cap is $0.07 Mil and 99.9% below the Biotechnology industry median of 113.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vincerx Pharma (VINC), the current Market Cap is $0.07 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VINC has been successfully added to your 